Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in the UK / NCT04871919
Active, not recruiting Observational

Prospective Observational Study of Filgotinib in Subjects With Rheumatoid Arthritis

NCT04871919 · tracked via the Priya Life Science UK tracker
Sponsor
Alfasigma S.p.A
Phase
Observational
Started
2021-05-11
Last updated
2026-10-28

Condition(s) studied

Rheumatoid Arthritis

Investigational drug(s) / intervention(s)

Filgotinib →

Filgotinib: Tablets are administered in accordance with the product label

Study summary

An observational study to describe the effectiveness, safety, and patient-reported outcomes in patients with moderate to severe active rheumatoid arthritis (RA) receiving filgotinib in real-world setting.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patients aged ≥ 18 years with a diagnosis of moderate to severe active RA being prescribed filgotinib in accordance with the local standard of care and product label for the first time. * Patients must be willing and able to use an electronic device to complete the study patient-reported outcome (PRO). Exclusion Criteria: \- Participation in any other interventional or non-interventional study without prior approval from the Medical Monitor. This does not preclude inclusion of patients enrolled to national registries.

Primary outcome measure(s)

  • Treatment persistence rates — Up to 24 months
    To evaluate the treatment persistence rate at 24 months, defined as the rate of patients continuing to receive filgotinib 24 months from treatment initiation.

Trial sites (89)

FacilityCityRegionStatus
Algemeen Stedelijk Ziekenhuis Aalst Belgium
Imelda VZW Bonheiden Belgium
AZ Sint-Jan Brugge-Oostende Bruges Belgium
Hôpital Erasme Brussels Belgium
Cliniques Universitaires Saint-Luc Brussels Belgium
Grand Hôpital de Charleroi asbl Charleroi Belgium
UZ Antwerpen Edegem Belgium
Reumacentrum Genk Genk Belgium
Reumaclinic Genk Genk Belgium
AZ Maria Middelares Ghent Belgium
Reuma Instituut Hasselt Belgium
UZ Leuven Leuven Belgium
CHU de Liège Liège Belgium
ZNA Jan Palfijn Merksem Belgium
CHU UCL Namur asbl - Site Godinne Yvoir Belgium
Rheumazentrum Kupka Altenburg Germany
Praxis für Rheumatologie - Amberg Amberg Germany
Rheumatology Center Prof. Neeck Bad Doberan Germany
Charité Campus Mitte, Klinik für Rheumatologie und Klinische Immunologie Berlin Germany
Rheumatologische Schwerpunktpraxis Berlin Germany
Rheumapraxis am Schlachtensee Berlin Germany
Rheumapraxis Mexikoplatz Berlin Germany
Klinik fur Innere Medizin - Rheumatologie - Kreiskrankenhaus Demmin Demmin Germany
Rheumatologisches MVZ Dresden Dresden Germany
Universitatsklinikum Dusseldorf Düsseldorf Germany
Praxis Dilltal Ehringshausen Germany
MVZ Ambulantes Rheumazentrum Erfurt Erfurt Germany
Universitätsmedizin Greifswald, Abteilung Innere Medizin A Greifswald Germany
Internistisch-Rheumatologische Arztpraxis Halle Germany
Rheumatologie im Struenseehaus Hamburg Germany
Praxis für Rheumatologie Hamburg Germany
Rheumazentrum Ruhrgebiet Herne Germany
Rheumapraxis Leipzig Germany
Praxis für Internistische Rheumatologie Leipzig Germany
Rheumatologische Facharztpraxis Magdeburg Germany
Rheumapraxis Mansfeld Germany
Praxis far Rheumatologie, Gastroenterologie und Innere Medizin München Germany
Rheumatologisches Praxiszentrum St. Bonifatius München Germany
Rheumapraxis Neubrandenburg Germany
Medizinischen Versorgungszentrums für Rheumatologie Planegg Germany

+ 49 more sites — see the full list on the official registry below.

More Alfasigma S.p.A. trials in the UK

OLE Study With Filgotinib in JIA Recruiting
A Study Evaluating the Effects of Filgotinib in Children and Teenagers With Ulcerative Colitis Recruiting
Prospective Observational Study of Effectiveness and Safety of Filgotinib in Participants With Ulcerative Colitis (UC) Active, not recruiting
A Study Evaluating the Effect of Filgotinib in Participants With Active Axial Spondyloarthritis Active, not recruiting
Safety, Tolerability, Pharmacokinetics, and Efficacy of Filgotinib for the Treatment of Polyarticular-course Juvenile Idiopathic Arthritis in Children and Adolescents Recruiting

Other trials for the same condition

A Study to Compare the Response to Treatment With Abatacept vs Adalimumab, on Background Methotrexate, in Adults With Early, Seropositive, and Shared Epitope-positive Rheumatoid Arthritis and an Inadequate Response to Methotrexate Active, not recruiting
A Study to Evaluate the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Participants With Active, Difficult to Treat Rheumatoid Arthritis Active, not recruiting
A Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid Arthritis Recruiting
Comprehensive Nano - Post Market Clinical Follow-Up Study Active, not recruiting
Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04871919 on ClinicalTrials.gov ↗ ← All trials in the UK